SS-31

🔬What Is SS-31

SS-31 (Elamipretide, MTP-131, Bendavia) is a mitochondria-targeting tetrapeptide (D-Arg-Dmt-Lys-Phe-NH2) that selectively binds to cardiolipin, a critical phospholipid found exclusively on the inner mitochondrial membrane. By stabilizing cardiolipin interactions with electron transport chain complexes, SS-31 optimizes mitochondrial electron flow, reduces excessive reactive oxygen species (ROS) production, and restores ATP synthesis efficiency. Preclinical and clinical studies (PROGRESS-HF, TAZPOWER, MMPOWER-3, ReCLAIM) have demonstrated its protective and restorative effects across cardiac, neurological, renal, and skeletal muscle tissues. It is one of the most advanced mitochondrial-targeted therapeutics in clinical development.

📊Clinical Studies & Results

SS-31 (Elamipretide/Bendavia) is a mitochondria-targeted tetrapeptide that selectively binds cardiolipin in the inner mitochondrial membrane:

• ▪FDA approved as FORZINITY™ for Barth syndrome in 2025, the first approved therapy targeting mitochondrial cardiolipin dysfunction
• ▪Phase II trial in heart failure with reduced ejection fraction (HFrEF) showed improvements in left ventricular end-systolic volume and 6-minute walk distance (Daubert et al., Circ Heart Fail, 2017; PMID: 28784652)
• ▪Stabilized cardiolipin structure and improved electron transport chain efficiency, reducing reactive oxygen species (ROS) production at the source rather than scavenging downstream
• ▪Long-term efficacy and safety data in Barth syndrome patients demonstrated sustained improvements in cardiac function and exercise capacity over 168 weeks
• ▪Protected against ischemia-reperfusion injury in cardiac, renal, and neuronal tissue by preserving mitochondrial cristae architecture
• ▪Improved mitochondrial bioenergetics in aging skeletal muscle, restoring ATP production to near-youthful levels in preclinical models

SS-31 represents a paradigm shift in mitochondrial medicine — rather than scavenging ROS after they form, it prevents their excessive generation by stabilizing the fundamental architecture of the inner mitochondrial membrane.

🏆Benefits

• FDA-Approved Mechanism – First therapy targeting mitochondrial cardiolipin, validated for Barth syndrome
• Prevents ROS at the Source – Stabilizes electron transport chain rather than scavenging free radicals downstream
• Cardiac Protection – Improved heart function metrics in clinical heart failure trials
• Ischemia-Reperfusion Shield – Protects heart, kidney, and brain tissue during oxygen deprivation events
• Restores Youthful ATP Production – Reverses age-related decline in mitochondrial bioenergetics
• Preserves Mitochondrial Architecture – Maintains cristae structure critical for efficient energy production

⚠️Possible Side Effects

• ▪Generally well tolerated in clinical trials with a favorable safety profile
• ▪Injection site reactions (mild pain, redness) are the most commonly reported side effect
• ▪No significant hemodynamic changes observed at therapeutic concentrations
• ▪No immunogenicity concerns reported in long-term studies
• ▪Transient mild headache or dizziness in rare cases
• ▪No impact on hormonal axes or metabolic parameters
• ▪Currently in active clinical trials – long-term safety data continues to accumulate

🎯Ideal For

• →Mitochondrial dysfunction and bioenergetic research
• →Cardiac protection and heart failure studies
• →Anti-aging protocols targeting cellular energy production
• →Ischemia-reperfusion injury prevention research
• →Combining with NAD+, MOTS-c, or Epithalon for comprehensive mitochondrial support
• →Age-related muscle weakness and exercise intolerance studies